Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
21.37
Nov 10 • 3:59 PM ET Dollar change+0.41 Percentage change(1.96%)
Aftermarket Close
21.45
Aftermarket • 7:30 PM ET Dollar change+0.08 Percentage change(0.37%)
Index
-
Market Cap
7.64B
Enterprise Value
12.29B
Income
-111.00M
Sales
5.42B
Book/sh
18.02
Cash/sh
1.44
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13000
IPO
May 06, 2022
P/E
-
Forward P/E
18.01
PEG
0.41
P/S
1.41
P/B
1.19
P/C
14.83
P/FCF
30.34
EV/EBITDA
13.45
EV/Sales
2.27
Quick Ratio
1.04
Current Ratio
1.56
Debt/Eq
0.79
LT Debt/Eq
0.78
Option/Short
Yes / Yes
EPS (ttm)
-0.31
EPS next Y
1.19
EPS next Q
0.37
EPS this Y
83.70%
EPS next Y
26.69%
EPS next 5Y
43.70%
EPS past 3/5Y
- -
Sales past 3/5Y
10.62% 8.38%
EPS Y/Y TTM
63.73%
Sales Y/Y TTM
8.88%
EPS Q/Q
212.03%
Sales Q/Q
7.34%
Insider Own
88.79%
Insider Trans
-0.06%
Inst Own
10.10%
Inst Trans
-0.44%
ROA
-0.80%
ROE
-1.73%
ROIC
-0.97%
Gross Margin
58.36%
Oper. Margin
9.41%
Profit Margin
-2.05%
SMA20
14.37%
SMA50
20.12%
SMA200
27.30%
Trades
Shs Outstand
357.39M
Shs Float
40.09M
52W High
21.36 0.05%
52W Low
14.44 47.99%
Volatility
3.65% 3.69%
ATR (14)
0.71
RSI (14)
75.18
Beta
0.51
Rel Volume
2.49
Avg Volume
604.09K
Volume
1,502,278
Perf Week
6.69%
Perf Month
32.98%
Perf Quarter
27.51%
Perf Half Y
33.31%
Perf YTD
25.12%
Perf Year
33.81%
Perf 3Y
33.23%
Perf 5Y
-
Perf 10Y
-
Prev Close
20.96
Price
21.37
Change %
1.96%
Consensus
Buy
Avg. Price Target
$21.92
Implied Upside
+2.6%
Analysts12incl. previous ratings
Rating Distribution6 Buy · 6 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 02, 2026Downgrade
HH.C. Wainwright
Buy → Neutral$22+2.9%
Oct 07, 2026Initiated
BCS logoBBarclays
Overweight$24+12.3%
Sep 09, 2026Initiated
LLeerink Partners
Outperform$24+12.3%
Jul 28, 2026Initiated
UBS logoUUBS
Buy$21-1.7%
Jan 05, 2026Downgrade
EVR logoEEvercore ISI
Outperform → In-line$18-15.8%
Dec 11, 2025Upgrade
C logoCCitigroup
Neutral → Buy$20-6.4%
Dec 02, 2025Upgrade
MS logoMMorgan Stanley
Equal-Weight → Overweight$21-1.7%
Oct 01, 2025Initiated
GS logoGGoldman
Neutral$16-25.1%
May 02, 2025Reiterated
HH.C. Wainwright
Buy$20 → $15-29.8%
Mar 28, 2025Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$24 → $15-29.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bernier Nathalie D.Former DirectorNov 03 '26Proposed Sale19.8840,022795,735Nov 03 11:29 AM
Munsch FrederickSVP, Controller and CAOOct 29 '26Option Exercise17.99112,0152,015,306157,846Nov 02 05:05 PM
Munsch FrederickSVP, Controller and CAOOct 29 '26Sale20.48112,0152,294,06745,831Nov 02 05:05 PM
Munsch FrederickOfficerOct 29 '26Proposed Sale20.48112,0152,294,349Oct 29 04:25 PM
Ling KarenFormer DirectorSep 28 '26Proposed Sale16.834,50075,735Sep 28 03:10 PM
Munsch FrederickSVP, Controller and CAOAug 10 '26Sale16.7852,900887,66245,831Aug 12 07:06 PM
VON ESCHENBACH ANDREW C.DirectorAug 06 '26Sale16.5012,500206,25069,792Aug 10 08:57 PM
VON ESCHENBACH ANDREW C.DirectorAug 07 '26Sale16.586,059100,45863,733Aug 10 08:57 PM
Munsch FrederickFormer OfficerAug 10 '26Proposed Sale16.7852,900887,885Aug 10 04:58 PM
VON ESCHENBACH ANDREW C.Former DirectorAug 07 '26Proposed Sale16.586,059100,430Aug 07 05:43 PM
VON ESCHENBACH ANDREW C.Former DirectorAug 06 '26Proposed Sale16.5012,500206,193Aug 06 03:11 PM
Bailey A Robert DEVP & Chief Legal OfficerMar 06 '26Buy17.1514,600250,332231,890Mar 10 05:23 PM
Eldessouky SamEVP and CFOMar 06 '26Buy17.134,00068,520403,130Mar 10 04:34 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMar 06 '26Buy17.1414,700251,958966,575Mar 10 04:32 PM
Ross Thomas W. Sr.DirectorMar 03 '26Buy17.684,50079,55664,891Mar 04 04:18 PM
Alfonso EduardoDirectorMar 02 '26Buy17.904,30076,9709,555Mar 03 04:26 PM
VON ESCHENBACH ANDREW C.DirectorFeb 27 '26Buy18.304,36479,88366,450Mar 03 04:24 PM
COLLIS STEVEN HDirectorFeb 23 '26Buy17.8115,000267,15020,255Feb 24 04:23 PM
ROBERTSON RUSSEL CDirectorFeb 20 '26Buy17.904,40078,76072,407Feb 24 04:16 PM
Ling KarenDirectorFeb 19 '26Buy17.744,00070,96841,676Feb 23 04:20 PM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Executive VP & CFOMr. Osama A. Eldessouky
Executive VP & Chief Legal OfficerMr. A. Robert D. Bailey
Ph.D.Dr. Yehia Hashad M.D.
President of Global Pharmaceuticals & International ConsumerMr. Andrew J. Stewart
Interim CEO & Chairman of the BoardMr. Thomas J. Appio